Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5941-5956

  Cruz Bustos, Teresa ^a   González González, Gloria ^a   Morales Sanfrutos, Julia ^a   Megía Fernández, Alicia ^a   Santoyo González, Francisco ^a   Osuna, Antonio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Actinomycin D; IgG; Nanoparticle; Protein A; Trypanosoma cruzi; Vinyl sulfone

Indexed keywords

ALKYL VINYL SULFONE DERIVATIVE; CYTOCHROME C; DACTINOMYCIN; GLYCOPROTEIN; IMMUNOGLOBULIN G; ISCOM; NANOCAPSULE; OVALBUMIN; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; DIVINYL SULFONE; LIPID; SULFONE;

AFFINITY CHROMATOGRAPHY; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CARBON NUCLEAR MAGNETIC RESONANCE; CENTRIFUGATION; CONJUGATION; CONTROLLED STUDY; DRUG PURIFICATION; ENZYME IMMUNOASSAY; FLUORESCENCE MICROSCOPY; FREEZE DRYING; HUMAN; HYDROLYSIS; HYDROPHOBICITY; IMMUNOGENICITY; IMMUNOLOGICAL TECHNIQUE; LIPOGENESIS; MICHAEL ADDITION; MORPHOLOGY; NONHUMAN; PROTEIN BINDING; PROTEIN PURIFICATION; PROTON NUCLEAR MAGNETIC RESONANCE; PURIFICATION; TRYPANOSOMA CRUZI; CHEMISTRY; DRUG FORMULATION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; ULTRASTRUCTURE;

TRYPANOSOMA CRUZI;

DRUG COMPOUNDING; IMMUNOGLOBULIN G; IMMUNOTHERAPY; ISCOMS; LIPIDS; NANOCAPSULES; SULFONES;

EID: 84875825956     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S35556     Document Type: Article

References (48)

1. Gregoriadis G. Enzyme-carrier potential of liposomes in enzyme replace-ment therapy. N Engl J Med. 1975;292(4):215.
2. Gregoriadis G. Homing of liposomes to target cells. Biochem Soc Trans. 1975;3(5):613-618.
3. Gregoriadis G, Neerunjun ED. Treatment of tumour bearing mice with liponsome-entrapped actinomycin D prolongs their survival. Res Commun Chem Pathol Pharmacol. 1975;10(2):351-362.
4. Segal AW, Gregoriadis G, Black CD. Liposomes as vehicles for the local release of drugs. Clin Sci Mol Med. 1975;49(2):99-106.
5. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6(5):797-808.
6. Lövgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix MTM adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10(4):401-403.
7. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine. 2009; 27(33):4388-4401.
8. Björkman C, Lundén A, Holmdahl J, Barber J, Trees AJ, Uggla A. Neospora caninum in dogs: detection of antibodies by ELISA using an iscom antigen. Parasite Immunol. 1994;16(12):643-648.
9. Chanlun A, Emanuelson U, Aiumlamai S, Björkman C. Variations of Neospora caninum antibody levels in milk during lactation in dairy cows. Vet Parasitol. 2006;141(3-4):349-355.
10. Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol Appl Biochem. 1988;10(2):161-172.
11. Slotved HC, Jensen L, Lind P. Comparison of the IFAT and Iscom-ELISA response in bovine foetuses with Neospora caninum infection. Int J Parasitol. 1999;29(8):1165-1174.
12. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308(5958):457-460.
13. Pandey RS, Babbar AK, Kaul A, Mishra AK, Dixit VK. Evaluation of ISCOM matrices clearance from rabbit nasal cavity by gamma scintigraphy. Int J Pharm. 2010;398(15):231-236.
14. Solano-Parada J, Gonzalez-Gonzalez G, Torró LM, et al. Effectiveness of intranasal vaccination against Angiostrongylus costaricensis using a serine/threonine phosphatase 2 A synthetic peptide and recombinant antigens. Vaccine. 2010;28(32):5185-5196.
15. Kodama S, Hirano T, Noda K, Umemoto S, Suzuki M. Nasal immuniza-tion with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2011; 29(10):1881-1890.
16. Björkman C, Jakubek EB, Arnemo JM, Malmsten J. Seroprevalence of Neospora caninum in gray wolves in Scandinavia. Vet Parasitol. 2010; 173(1-2):139-142.
17. Frössling J, Bonnett B, Lindberg A, Björkman C. Validation of a Neospora caninum iscom ELISA without a gold standard. Prev Vet Med. 2003;57(3):141-153.
18. Malmsten J, Jakubek E-B, Björkman C. Prevalence of antibodies against Toxoplasma gondii and Neospora caninum in moose (Alces alces) and roe deer (Capreolus capreolus) in Sweden. Vet Parasitol. 2011;177(3-4): 275-280.
19. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1996;13(1-2):1-55.
20. Kersten GF, Spiekstra A, Beuvery EC, Crommelin DJ. On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochim Biophys Acta. 1991;1062(2):165-171.
21. Kersten GF, Teerlink T, Derks HJ, et al. Incorporation of the major outer membrane protein of Neisseriagonorrhoeae in saponin-lipid complexes (iscoms): chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems. Infect Immun. 1988;56(2):432-438.
22. Akerblom L, Nara P, Dunlop N, Putney S, Morein B. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Biotechnol Ther. 1993;4(3-4):145-161.
23. Heeg K, Kuon W, Wagner H. Vaccination of class I major histocompat-ibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur J Immunol. 1991;21(6):1523-1527.
24. Sjölander S, Hansen JE, Lövgren-Bengtsson K, Akerblom L, Morein B. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems. Vaccine. 1996;14(4):344-352.
25. Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology. 1991;72(3):317-322.
26. Meadows DC, Gervay-Hague J. Vinyl sulfones: synthetic preparations and medicinal chemistry applications. Med Res Rev. 2006;26(6): 793-814.
27. Simpkins NS. The chemistry of vinyl sulphones. Tetrahedron. 1990; 46(20):6951-6984.
28. Lopez Jaramillo F, Hernandez Mateo F, Santoyo Gonzalez F. Vinyl sulfone: a multi-purpose function in proteomics. In: Eastwood Leung H-C, editor. Integrative Proteomics. Croatia: InTech; 2012:301-326.
29. Morales-Sanfrutos J, Lopez-Jaramillo J, Ortega-Muñoz M, et al. Vinyl sulfone: a versatile function for simple bioconjugation and immobilization. Org Biomol Chem. 2010;8(3):667-675.
30. Sarada R, Pillai MG, Ravishankar GA. Phycocyanin from Spirulina sp: influence of processing of biomass on phycocyanin yield, analysis of efficacy of extraction methods and stability studies on phycocyanin. Process Biochemistry. 1999;34(8):795-801.
31. Morales-Sanfrutos J, Megia-Fernandez A, Hernandez-Mateo F, Giron-Gonzalez MD, Salto-Gonzalez R, Santoyo-Gonzalez F. Alkyl sulfonyl derivatized PAMAM-G2 dendrimers as nonviral gene delivery vectors with improved transfection efficiencies. Org Biomol Chem. 2011;9(3): 851-864.
32. Rönnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine. 1995;13(14):1375-1382.
33. Papadopoulou G, Karagouni E, Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine. 1998;16(9-10):885-892.
34. Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T. On the preparation, microscopic investigation and application of ISCOMs. Micron. 2006;37(8):724-734.
35. Ruiz-Perez LM, Osuna A, Lopez MC, et al. Activity of rhodium(III) complexes against Trypanosoma cruzi. Arzneimittelforschung. 1988; 38(2):312-314.
36. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
37. De Pablos LM, González GG, Solano Parada J, et al. Differential Expression and Characterization of a Member of the Mucin-Associated Surface Protein Family Secreted by Trypanosomacruzi. Infect Immun. 2011;79(10):3993-4001.
38. Coe JE, Coe PR, Ross MJ. Staphylococcal protein A purification of rodent IgG1 and IgG2 with particular emphasis on syrian hamsters. Mol Immunol. 1981;18(11):1007-1012.
39. Graille M, Stura EA, Corper AL, et al. Crystal structure of a Staphylococcusaureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A. 2000;97(10):5399-5404.
40. Shpigel E, Goldlust A, Eshel A, et al. Expression, purification and applications of staphylococcal protein A fused to cellulose-binding domain. Biotechnol Appl Biochem. 2000;31(Pt 3):197-203.
41. Guss B, Uhlén M, Nilsson B, Lindberg M, Sjöquist J, Sjödahl J. Region X, the cell-wall-attachment part of staphylococcal protein A. Eur J Biochem. 1984;138(2):413-420.
42. Uhlén M, Guss B, Nilsson B, Gatenbeck S, Philipson L, Lindberg M. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem. 1984;259(3): 1695-1702.
43. Harbers E, Mueller W. On the inhibition of RNA synthesis by actinomycin. Biochem Biophys Res Commun. 1962;7:107-110.
44. Waksman SA, Geiger WB, Reynolds DM. Strain Specificity and Production of Antibiotic Substances: VII. Production of Actinomycin by Different Actinomycetes. Proc Natl Acad Sci U S A. 1946;32(5): 117-120.
45. Fernandes JF, Halsman M, Castellani O. Effect of actinomycin D on the infectivity of Trypanosoma cruzi. Nature. 1965;207(5000): 1004-1005.
46. Gentil LG, Cordero EM, do Carmo MS, dos Santos MR, da Silveira JF. Posttranscriptional mechanisms involved in the control of expression of the stage-specific GP82 surface glycoprotein in Trypanosoma cruzi. Acta Trop. 2009;109(2):152-158.
47. Kerr ID, Lee JH, Farady CJ, et al. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem. 2009;284(38): 25697-25703.
48. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17(1):31-48.